| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,3 M € | +209.2% | 2,0 M € | +62.6% | 1,3 M € | — | — | — | — | — | — | — | — | — | ||||||||||
| Gross margin | — | — | — | 2,2 M € | -12.0% | 2,5 M € | -22.4% | 3,3 M € | -35.2% | 5,0 M € | +6.6% | 4,7 M € | +7.2% | 4,4 M € | +59.5% | 2,8 M € | +103.5% | 1,4 M € | +522.9% | 218,1 k € | ||||
| EBITDA | 2,4 M € | +321.9% | -1,1 M € | +43.4% | -1,9 M € | +11.0% | -2,1 M € | -41.6% | -1,5 M € | -407.5% | -294,2 k € | -117.3% | 1,7 M € | -22.4% | 2,2 M € | -8.5% | 2,4 M € | +31.7% | 1,8 M € | +66.0% | 1,1 M € | +13042.5% | 8,3 k € | |
| Operating profit | -690,4 k € | +74.5% | -2,7 M € | +5.0% | -2,9 M € | +54.1% | -6,2 M € | -7.5% | -5,8 M € | -11.7% | -5,2 M € | -99.5% | -2,6 M € | -366.8% | -555,5 k € | -640.5% | 102,8 k € | -82.4% | 585,2 k € | -23.0% | 760,2 k € | +635.5% | -141,9 k € | |
| Profit/loss | -1,6 M € | +58.0% | -3,8 M € | -14.3% | -3,3 M € | +49.1% | -6,5 M € | -13.1% | -5,8 M € | -11.2% | -5,2 M € | -113.9% | -2,4 M € | -322.4% | -573,5 k € | -765.0% | -66,3 k € | -107.8% | 846,8 k € | -13.9% | 983,4 k € | +19363.4% | 5,1 k € | |
| Equity | 3,6 M € | +152.5% | -6,9 M € | -120.9% | -3,1 M € | +49.4% | -6,2 M € | -2025.6% | 321,9 k € | -94.7% | 6,1 M € | -46.0% | 11,3 M € | +98.0% | 5,7 M € | -9.5% | 6,3 M € | +22.5% | 5,1 M € | +62.2% | 3,2 M € | +2197.6% | 137,6 k € | |
| Total assets | 17,2 M € | +26.9% | 13,5 M € | +23.8% | 10,9 M € | +52.7% | 7,2 M € | -37.1% | 11,4 M € | +10.4% | 10,3 M € | -21.3% | 13,1 M € | +82.9% | 7,2 M € | -14.4% | 8,4 M € | +30.2% | 6,4 M € | +60.4% | 4,0 M € | +1601.6% | 235,5 k € | |
| Cash | 1,6 M € | +108.9% | 784,7 k € | +27.2% | 617,1 k € | -41.8% | 1,1 M € | -81.3% | 5,7 M € | -1.6% | 5,8 M € | -39.8% | 9,6 M € | +127.7% | 4,2 M € | -7.0% | 4,5 M € | -6.7% | 4,9 M € | +73.5% | 2,8 M € | +2328.1% | 115,2 k € | |
| Debts | 13,4 M € | -34.4% | 20,3 M € | +46.1% | 13,9 M € | +5.1% | 13,3 M € | +20.9% | 11,0 M € | +159.7% | 4,2 M € | +154.7% | 1,7 M € | +12.6% | 1,5 M € | -29.0% | 2,1 M € | +99.9% | 1,0 M € | +59.2% | 651,3 k € | +1055.5% | 56,4 k € | |
| Staff | 46,1 | 51,3 | 53,7 | 53,5 | 51,9 | 47 | 43,3 | 34,4 | 27,2 | 13,7 | 3,3 | 2,5 | ||||||||||||
Public limited company · Gent · incorporated on 31/05/2013 · 46,1 ETP
Public limited company loss-making in the latest fiscal year. Cash position rising (+108.9%).
Solid counterparty for a standard engagement.
Inbiose is a Public limited company incorporated in 2013. Its main activity is: Manufacture of other chemical products n.e.c.. Its registered office is in Gent. It employs on average 46,1 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette